Close Menu

Clear Labs Clear Safety NGS Platform

Feb 19, 2019

Clear Labs has released a software update for its Clear Safety NGS platform, which now includes Salmonella serotyping. According to the firm, food safety professionals can now detect up to 40 unique Salmonella serotypes in an enriched sample in about 24 hours. With the update, Clear Labs said that the platform allows food manufacturers and service labs to test for the presence or absence of pathogens and serotypes at the same time. In addition, the firm noted that customers can now choose if they want to test for the disease at the genus level, species level, or the serotype level. 

More Like This

Mar 31, 2020

Berkeley Lights OptoSeq 3' mRNA Library Kit

Berkeley Lights has launched its OptoSeq 3' mRNA Library kit, which allows users to directly link phenotype to genotype. The kit inculdes reagents, primers, probes, and enzymes to prepare and label individual cells for cDNA sequencing. 

According to the firm, customers can use the library prep kit to capture and link genomic information to single-cell phenotypic data in order to learn more about cellular behavior and ramp up discovery, development, and production of cell-based products. 

Mar 30, 2020

Phase Scientific Phasify Viral RNA Extraction Kit

Phase Scientific, which is headquartered in Hong Kong with R&D and manufacturing facilities in Southern California and mainland China, has globally launched the Phasify Viral RNA Extraction Kit, which purifies and concentrates viral RNA in patient viral transport media samples. Phasify is a proprietary technology developed by Phase Scientific that can concentrate target molecules 10-fold to 100-fold, making them easier to detect. The kit can be used with sample volumes of up to 1 ml, and can produce enhanced viral RNA concentration with flexible elution volume up to 10 µl. According to the company, the kit enables a three- to six-cycle threshold reduction compared to solid phase extraction.

Mar 20, 2020

Asuragen Armored RNA Quant SARS-CoV-2 Control

Asuragen is offering an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic. The new control material targets the SARS-CoV-2 viral nucleocapsid region and, along with the company's new RNAse P construct, aligns with the US Centers for Disease Control and Prevention- and World Health Organization-recommended diagnostic panel. Asuragen said that armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.

Mar 20, 2020

LGC SeraCare AccuPlex SARS-CoV-2 Reference Material Kit

LGC SeraCare recently launched the AccuPlex SARS-CoV-2 Reference Material Kit, which contains positive reference material targeting the published US Centers for Disease Control and Prevention and World Health Organization consensus sequences, as well as complementary negative reference material targeting the human RNAse P gene. LGC SeraCare said that its kit is superior to "naked" transcribed RNA which does not evaluate the assay extraction step, and safer than heat-treated infectious samples, and are a valuable tool for clinical laboratories seeking to perform assay installation, verification, and performance monitoring.

Mar 20, 2020

Arima Genomics HiChIP Assay and MAPS Pipeline

Arima Genomics has launched its HiChIP chromatin conformation assay. The assay is built on its Arima-HiC platform and introduces chromatin immunoprecipitation sequencing to provide data on long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest.

The firm has also created an optimized version of the Model-based Analysis of Proximity Ligation-Assisted ChIP-seq and HiChIP (MAPS) bioinformatics pipeline to help streamline data analysis.

Mar 20, 2020

Twist Bioscience SARS-CoV-2/COVID-19 NGS Target Enrichment Panel

Twist Bioscience is offering a research-use-only target enrichment panel for viral detection and characterization of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing. The panels, comprising synthetic double-stranded DNA probes covering the entire viral genome, can also be used for environmental monitoring and surveillance. Kits are available in three sizes: 2 reactions, 12 reactions, and 96 reactions.

Mar 20, 2020

Oncocyte DetermaIO

Oncocyte said it has completed CLIA Validation for and launched DetermaIO, previously the Insight Genetics IM Score Test. The test is now available for research use within the biopharmaceutical and academic communities. DetermaIO is a gene expression profile test that evaluates the immune microenvironment in biopsies from cancer patients to identify individuals more or less likely to respond to anti-PD-1/PD-L1 immunotherapy.  The test differentiates itself from other immunotherapy diagnostic tests by having the capability to determine if the immune microenvironment is active or quiescent. DetermaIO has the potential to be used to stratify patients in the more than 3,000 PD-1/PD-L1 ongoing clinical trials that are collectively expected to recruit over 500,000 patients, the company said.

Mar 20, 2020

DNAstack COVID-19 Beacon

DNAstack has released Beacon for SARS-CoV-2, the virus that causes COVID-19, to enable the scientific and medical communities to share and discover knowledge about the genetics of the virus in real time. Beacon, which is available here, will allow information about genetic variants to be shared instantly using software that follows an open international standard, the company said.

Researchers can use the new Beacon to discover sequences with specific genetic mutations and map their geographic and evolutionary origins. The platform integrates derivative data from genetic sequencing libraries such as GISAID and links to Nextstrain pathogen evolution visualizations. 

The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH). The system is deployed on Microsoft Azure, a cloud computing platform with global reach and scalability.

Mar 19, 2020

Paragon Genomics CleanPlex SARS-CoV-2 NGS Panel

Paragon Genomics has launched its CleanPlex SARS-CoV-2 Panel for COVID-19 coronavirus detection, tracking, and research through amplicon-based target enrichment for next-generation sequencing applications. According to the firm, the panel covers the entire genome of the SARS-CoV-2 virus responsible for the global COVID-19 pandemic. Paragon said that the panel's four-step workflow converts viral RNA into sequencing-ready libraries within five hours. Powered by Paragon's CleanPlex's technology, versions of the panel are available for both the Illumina and MGI sequencing platforms. 

Paragon is also offering free consultation for researchers interested in designing custom NGS panels for coronavirus research.

Mar 13, 2020

Bio-Rad Exact Diagnostics SARS CoV-2 Standard

Bio-Rad has launched a standard for SARS-CoV-2 testing through its Exact Diagnostics product line. The standard contains synthetic RNA transcripts of the virus as well as human genomic DNA, enabling labs to test the entire process of a molecular assay, including extraction, amplification, and detection of the virus.

Mar 13, 2020

Microbiologics Synthetic RNA for SARS-CoV-2

Microbiologics is now offering synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19. The material mimics the viral nucleic acid and provides the exact targets specified by the US Centers for Disease Control and Prevention for test development, the company said.

Specifically, it is a 1,044-nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for detection of 2019 novel coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The RNA is available in two different concentrations: 1x106 and 1x109 genome copies per tube. The material can be shipped within the USA without handling restrictions or permitting requirements. The company noted that permits may be required outside the USA and interested parties should check with local authorities.

Mar 12, 2020

Twist Bioscience Synthetic SARS-CoV-2 RNA Controls

Twist Bioscience has made two synthetic SARS-CoV-2 RNA controls available for use in quality control in the development and validation of next-generation sequencing- and reverse-transcription PCR-based tests.

The sequence-verified controls are designed to cover the full viral genome of two specific virus variants: MN908947.3, considered the reference genome, isolated from a patient in Wuhan, China, and MT007544.1, isolated from a patient in Australia.

Twist noted that customers purchasing synthetic controls are subject to the firm's biosecurity screening protocols.

Mar 11, 2020

ZeptoMetrix NATtrol SARS-CoV-2 Recombinant Construct

ZeptoMetrix has released its newly inactivated and non-infectious NATtrol SARS-CoV-2 Recombinant construct for laboratory quality control and test validation.

This non-infectious quality control incorporates a recombinant construct associated with targeted detection regions of the virus that may be used in the development of molecular assays designed to detect SARS-CoV-2. It can also be used in BSL-2 facilities in place of the live virus, as non-infectious, external quality controls for assays developed to detect SARS-CoV-2, the company said.

Mar 10, 2020

Fluidigm AccuLift Laser Capture Microdissection System

Fluidigm has launched the AccuLift Laser Capture Microdissection System, which enables precise and efficient capture of individual cells or larger tissue regions from frozen and FFPE tissue sections for DNA, RNA, and protein biomarker analysis using sequencing, real-time PCR, or mass spectrometry. Fluidigm said that it collaborated with Lance Liotta, codirector of the Center for Applied Proteomics and Molecular Medicine at George Mason University, to develop the AccuLift product portfolio. The new system features a patent-pending design including a high-precision stage and uniquely aligned IR and UV lasers. It also features a new capture method developed in Liotta's laboratory that increases the efficiency of cellular capture and extraction.

Mar 10, 2020

BioDynami NGS RNA Library Prep Kit

BioDynami has released a new sequencing library preparation product called NGS RNA Library Prep Kit. It takes 3 ng to 100 ng of purified RNA as input material, is compatible with different types of indexes for multiplexing, and is designed for Illumina sequencing. The workflow takes 2 hours in total, with 10 minutes of hands-on time.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.